We have all heard of Alzheimer’s disease. Many of us know someone who has been affected by this devastating disease. The clinical facts associated with Alzheimer’s disease are stark.
• There is no cure for Alzheimer’s disease.
• We do not know the cause of Alzheimer’s disease.
• There are no effective treatments for Alzheimer’s disease.
While 50 years of research has revealed much about Alzheimer’s disease it has not resulted in significant benefits to anyone unfortunate enough to be diagnosed with the disease. During these 50 years one factor, human exposure to aluminium, has been consistently linked to Alzheimer’s disease. In a recent invited paper, the world’s leading authority on human exposure to aluminium, concluded (after considering this for 30 years) that under certain conditions
‘it was inevitable that aluminium played a contributory role in Alzheimer’s disease’ (journal.frontiersin.org).
There has not been a single significant clinical trial to test the role of aluminium in Alzheimer’s disease during this time.
Professor Christopher Exley has pioneered research into the natural history of aluminium, and most recently human exposure to aluminium, for over 30 years. He now believes that the weight of evidence, which implicates aluminium in Alzheimer’s disease, is so unequivocal that this must be tested in a large-scale clinical trial.
We are asking for the public’s help to support Professor Exley’s crowdfunding campaign to raises funds for a clinical trial which will establish once and for all if human exposure to aluminium is a contributory factor in Alzheimer’s disease.
Full details of the proposed clinical trial, the funding required to carry it out and how the public can support the trial can be found at on Professor Exley’s Campaign Page which launches on the 14 July 2015
You can also find updates @FutSciNow and follow Prof Exley on Twitter @profchris15 and on Instagram
If this trial goes ahead and it implicates aluminium in Alzheimer’s disease this will mean that, for the very first time, there will be an effective, non-invasive, inexpensive and non-drug-based therapy against the ravages of Alzheimer’s disease.
This is a truly exciting possibility for the future treatment of Alzheimer’s disease. Thank you for your support.
Further details about this appeal and the proposed trial can be obtained by contacting Professor Chris Exley (c.exley@keele.ac.uk)
